Go here to learn more or to get a mailed copy.
Many people look forward to summer – a little lighter work schedule, less traffic, a long-anticipated trip, longer days, outdoor entertainment. But if you’re experiencing cancer, you may not feel like you get a “summer break.” Chemo treatments, radiation therapy schedules, and monitoring don’t stop between June and August. Adding. Read More
Research Update from AACR 2022, Part 2 The American Association for Cancer Research Annual Meeting 2022 was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. In Part 2, we highlight two. Read More
The American Association for Cancer Research Annual Meeting was held in New Orleans in April. Dr. Andrea Miyahira, PCF’s Director of Global Research and Scientific Communications, has identified key updates that were presented at the meeting. This week, we highlight two presentations on potential ways to optimize the use of. Read More
We get a lot of questions about what to eat when you’re traveling, or when you’re at an event and don’t have a lot of healthy options. During the pandemic, there has been less travel and fewer parties, but as we emerge from each new wave, we may encounter more. Read More
National Minority Health Month is observed each year in April to raise awareness of health disparities among racial and ethnic minority communities and spur action to overcome these injustices. The origin dates back to 1915, when Black educator and leader Booker T. Washington launched National Health Improvement Week (later National. Read More
Informing care for intermediate-risk cancer, a new imaging tracer, and understanding the effects of PSA screening recommendations Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances. Read More
What this means for patients: Today, a new treatment known as 177lutetium-PSMA-617 (Lu-PSMA; trade name PluvitcoTM) was approved by the FDA for certain patients with advanced prostate cancer. This medicine delivers a small dose of radiation attached to a molecule that specifically binds to prostate cancer cells. It has been shown to. Read More
In the U.S., 1 in 8 men in their lifetime will be diagnosed with prostate cancer. But the disease does not affect all men equally. 1 in 6 Black men will be diagnosed with prostate cancer in their lifetime and they are more than 2 times as likely to die. Read More
It’s spring. That means the grocery stores will begin to fill with a glorious abundance of seasonal fruits and vegetables. For some, April also means a family gathering filled with traditional Easter dishes and Easter bunny treats. Whether you celebrate Easter or just worship the leaves and flowers popping through. Read More
Combination treatments for metastatic disease Clinicians and researchers gathered last month at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) — some in-person in San Francisco, some tuning in virtually. Hundreds of presentations covered advances in screening, diagnosis, treatment, monitoring, and survivorship in prostate and other GU. Read More